Back to search
Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Core Binding Factor Acute Myeloid Leukemia (CBF-AML) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Core Binding Factor Acute Myeloid Leukemia (CBF-AML) trials you may qualify forFor newly diagnosed high-relapse-risk core-binding-factor acute myeloid leukemia participants, the investigators aim to perform allogeneic hematopoietic stem ce…
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochlorid…
The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia w…
This phase II MyeloMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen)…
Acute Core Binding Factor leukemias represent a specific category of acute myeloid leukemias that share prognostic factors, a specific mutational profile, and a…